Analyst firms · Raymond James · MIRM

Raymond James MIRM price target and rating history

Mirum Pharmaceuticals Inc. (MIRM) · Health Care

Raymond James rates Mirum Pharmaceuticals Inc. (MIRM) Strong Buy with a $74 price target, as of its latest action on Mar 11, 2022. It has published 4 rating actions on MIRM since September 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a MIRM price target in the last 12 months, the median target is $145.

Current rating
Strong Buy
Price target
$74
Median target, all firms
$145
Actions on MIRM
4

Raymond James price target on MIRM

$74$63$5120222023202420252026
Raymond James price target on MIRM, each point a stated target, September 2021 to March 2022.

Every Raymond James rating on MIRM

How other firms rate MIRM

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
CitigroupBuy$145Jun 2, 2026
Wolfe ResearchOutperform$145May 19, 2026
RBC Capital MarketsOutperform$130Feb 18, 2026

Questions about Raymond James and MIRM

What is Raymond James's price target for MIRM?
Raymond James's latest stated price target for Mirum Pharmaceuticals Inc. (MIRM) is $74, from its action on Mar 11, 2022.
What is Raymond James's rating on MIRM?
Raymond James rates MIRM Strong Buy, a bullish rating, as of Mar 11, 2022.
When did Raymond James last change its view on MIRM?
On Mar 11, 2022, Raymond James raises its price target to $74 from $70, keeps Strong Buy.
How does Raymond James's MIRM target compare with other analysts?
Across 3 firms with a MIRM price target in the last 12 months, the median target is $145.

More MIRM rating histories

All Raymond James ratingsMIRM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.